Neumora shakes up C-suite a month after depression drug fails first Phase 3 trial

Kyle LaHucik

Senior Reporter

In a surprise move Thursday, Neumora remade its executive team and brought back its former CEO, following last month’s failure of the brain health biotech’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Neumora shakes up C-suite a month after depression drug fails first Phase 3 trial

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Updated: Kennedy is confirmed to lead HHS, putting anti-vaccine advocate and drug industry skeptic atop US health ...

Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Newleos, a new biotech with $93.5M, repurposes Roche's experimental CNS drugs

Hunger-suppressing biotech Aardvark raises $94M in IPO

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Neumo­ra shakes up C-suite a month af­ter de­pres­sion drug fails first Phase 3 tri­al

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Neumora shakes up C-suite a month after depression drug fails first Phase 3 trial